Improving immune therapy for liver cancer by targeting specific immune cells
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer
This study is looking at a new way to improve treatment for liver cancer by using a special protein in immune cells and a type of bacteria, hoping to help patients get better results from their therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-11172570 on NIH RePORTER |
What this research studies
This research focuses on enhancing immune checkpoint therapy for hepatocellular cancer (HCC) by targeting a specific protein called KLF2 in macrophages. The researchers have developed a unique mouse model that closely mimics human liver cancer, allowing them to study how the immune system interacts with tumors. They are investigating a novel approach that combines immune therapy with a specific type of bacteria to improve treatment outcomes. By understanding the cellular and molecular mechanisms involved, the goal is to create more effective therapies for patients with HCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular cancer who are seeking new treatment options.
Not a fit: Patients with liver cancer who are not eligible for immune checkpoint therapies or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for liver cancer, potentially improving survival rates for patients.
How similar studies have performed: Other research has shown promise in enhancing immune therapies through innovative approaches, suggesting potential for success in this area.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Li, Guangfu — University of Connecticut Sch of Med/dnt
- Study coordinator: Li, Guangfu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.